Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center,…
Browsing: AML
Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) In a captivating interview, Yasmin Abaza, MD, an esteemed Assistant Professor of…
Tapan Kadia, MD- Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX In this presentation…
Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center The presentation…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center.…
Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer…
The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is…
In this discussion, the focus is on optimizing Acute Myeloid Leukemia (AML) treatment. The idea of reducing drug doses upon…
The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center.…
Alexander Edward Perl, MD, MS is a member of the leukemia program in the Abramson Cancer Center of the University…
Brian Andrew Jonas, MD, Ph.D. Associate Professor of Medicine (Clin X) – UC Davis Comprehensive Cancer Center Brian Jonas MD, Ph.D.…
Farhad Ravandi-Kashani, M.D. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston,…
Aaron Logan, MD – Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) Meet Aaron…
Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…
iFrame is not supported! Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study…
Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination…
CPI-613 (Devimistat) + Cytarabine + Mitoxantrone in Acute Myeloid Leukemia (AML) FDA Fast Track Designation CPI-613 (Devimistat) Demonstrates Positive Outcomes…